Pathstone Family Office’s Omnicell OMCL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$355K Sell
7,886
-946
-11% -$57.3K ﹤0.01% 1210
2023
Q2
$669K Sell
8,832
-97
-1% -$6.54K 0.01% 628
2023
Q1
$524K Sell
8,929
-17,974
-67% -$991K 0.01% 674
2022
Q4
$1.25M Buy
26,903
+6,743
+33% +$405K 0.01% 688
2022
Q3
$1.75M Buy
20,160
+8,082
+67% +$849K 0.02% 488
2022
Q2
$1.37M Sell
12,078
-347
-3% -$39.8K 0.03% 276
2022
Q1
$1.74M Sell
12,425
-61
-0.5% -$8.79K 0.04% 196
2021
Q4
$2.25M Sell
12,486
-2,180
-15% -$378K 0.06% 170
2021
Q3
$2.18M Buy
14,666
+2,370
+19% +$363K 0.06% 154
2021
Q2
$1.86M Buy
12,296
+3,732
+44% +$520K 0.06% 163
2021
Q1
$1.11M Buy
+8,564
New +$1.1M 0.04% 193
2019
Q2
Sell
-40
Closed -$3K 823
2019
Q1
$3K Buy
+40
New +$2.99K ﹤0.01% 702

Other funds holding OMCL

Pathstone Family Office's OMCL Position: Q3 2023 in Review

Pathstone Family Office reduced its Omnicell (OMCL) stake by 11% in Q3 2023, selling an estimated $57.3K and leaving 7,886 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #1210.

Pathstone Family Office first reported a position in OMCL in Q1 2019 and has held it in 12 quarters since. The position peaked at $2.25M in Q4 2021. 312 funds tracked by Wall St. Rank hold OMCL as of Q3 2023.

  • Pathstone Family Office held 7,886 shares of Omnicell worth $355K as of Q3 2023.
  • Pathstone Family Office sold 946 Omnicell shares in Q3 2023, an estimated $57.3K.
  • Omnicell made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1210 holding.
  • Pathstone Family Office first reported a position in Omnicell in Q1 2019 and has held it in 12 quarters since.
  • Pathstone Family Office's Omnicell position peaked at $2.25M in Q4 2021.
  • 312 funds tracked by Wall St. Rank held Omnicell as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.